



## Clinical Strategy Steering Committee Charter

**COMMITTEE GOAL/MISSION:** To define and prioritize key clinical focus areas, increase coordination across organizational silos, and support BCBSMA in taking a proactive and efficient approach to clinical strategy, ultimately enhancing the quality and value of care delivered to members.

**COMMITTEE PURPOSE** the CSSC is responsible for identifying opportunities for clinical improvement, endorsing strategic initiatives, and overseeing progress toward clinical goals. The committee drives integration across business functions and enables faster, more informed decision-making.

**EXECUTIVE SPONSOR(s):** Sandhya Rao, CMO

**CHAIR(s):** Karl Laskowski, Vice President, Clinical Programs and Strategy, Rachel Voroboyev VP Product

**MEMBERSHIP:**

Name	Title	Department
Sandhya Rao	CMO	
Karl Laskowski	VP Clinical Strategy and Sr Medical Director	HMM
Stephan Katinas	Sr VP Network Payment Innovation and Contract Management	NPC
Mark Friedberg	SVP Performance Measurement and Improvement	PMI
Paul Sweeney	SVP Chief Sales and Marketing Officer	Sales
Dave Corkum	SVP Products and Commercial Segment	
Michael Guerriere	SVP Chief Actuary	Actuary
Melissa Horrnie	VP Deputy General Counsel	Legal
	VP Gov Regulatory Affairs	GRA
Ashley Yeats	VP Medical Operations, Sr Medical Director	HMM
Deb Vona	VP Clinical Operations	HMM
Mary Beth Erwin	VP Chief Pharmacy Officer	HMM
Doug Wilson	Engineering Director and Value Stream Lead	ET
Judy Bouthot	Sr Director Q&C, Cost and Trend	HMM



## [Name] Committee Charter

Membership will be reviewed and updated no less than annually by the Committee Chairs.

**MEETINGS:** The committee meets monthly for one hour. Meetings will include review of clinical data, discussion of strategic initiatives, progress updates, and agenda items defined in advance by the chair. Meeting activities are documented by designated support staff.

The frequency of the meetings will be reviewed on a yearly basis. Committee members are expected to attend all meetings but may be represented by an appropriate replacement in their absence.

### **OBJECTIVES**

- Review and evaluate clinical data and leading indicators of opportunity
- Define and approve prioritized focus areas
- Endorse and oversee proposed solutions from functional areas
- Define and monitor metrics for success
- Evaluate progress at regular intervals

**DECISION-MAKING:** The committee will make decisions based on discussion and consensus. If consensus cannot be reached on critical issues, the matter will be escalated to executive leadership. The committee has authority to prioritize focus areas and endorse clinical initiatives within organizational guardrails.

### **EXPECTED OUTCOMES:**

- Clear prioritization of clinical focus areas
- Documented strategies and endorsed initiatives
- Measurable goals and progress metrics
- Increased integration and efficiency in clinical strategy execution

### **REPORTING STRUCTURE OF COMMITTEE:**

Reports will be shared with executive leadership on a regular cadence, summarizing key decisions, initiatives endorsed, progress toward goals, and any issues requiring executive attention.

### **CONFIDENTIALITY**

In conducting its business, members of the Committee will take special care, consistent with the Company's Code of Ethics and Conduct (the Blueprint) to protect the confidentiality of sensitive information it receives.

### **CONFLICTS OF INTEREST**

Committee members will promptly disclose any conflict of interest they may have with respect to any matter to be discussed by the Committee.



## [Name] Committee Charter

**POLICIES:** NA

**ANNUAL REVIEW:** The Committee Charter will be reviewed and updated annually, and when significant changes occur such as leadership changes, changes in focus to respond to revised corporate priorities, changes in reporting, changes in decision making authority and/or structure, and/or responding to external changes such as regulatory updates.

**Document Information:** [Version control and record of annual review and updates.]

**REVISION HISTORY:**

Version	Date	Revision Summary
1.0	3/10/24	Initial Charter Approval

**DOCUMENT OWNER:**

Name	Organization

**REVIEWERS:**

Name	Division	Versions